• Mashup Score: 0

    The FDA cleared the investigational new drug application for ExeGi Pharma LLC’s, EXE-346, a live biotherapeutic biologic drug intended for patients with ileal pouch-anal anastomosis who experience excessive stool frequency.Patients who undergo ileal pouch-anal anastomosis – or J-pouch procedure – may later experience excessive stool frequency of six or more times daily, with

    Tweet Tweets with this article
    • The @US_FDA cleared the investigational new drug application for @ExeGiPharma's EXE-346, a live #biotherapeutic biologic drug intended for #patients with #ilealpouch-#anal #anastomosis who experience excessive #stool frequency #GITwitter #MedTwitter https://t.co/UdXVkWrRFq